Read time: 3:30 mins
The value of lipid biomarkers for precision medicine is growing in recognition, resulting in an increased research focus on translational lipidomic workflows. Underpinning advances in this field are developments in mass spectrometry (MS) and liquid chromatography (LC). In this editorial, David Peake (Thermo Fisher Scientific) considers the analytical challenges associated with translational lipid biomarker development, and how the latest LC–MS technologies and lipidomics workflows are overcoming them.
Read time: 3:30 mins
2017 White Paper on recent issues in bioanalysis: aren’t BMV guidance/guidelines ‘Scientific’? (Part 1 – LCMS: small molecules, peptides and small molecule biomarkers)
This White Paper is from the 2017 11th Workshop on Recent Issues in Bioanalysis (11th WRIB) that took place in Los Angeles/Universal City, California from 3 April 2017 to 7 April 2017. The conference included a full week of bioanalysis, biomarkers and immunogenicity.
An author’s perspective: Ragu Ramanathan on an LC–MS/HRMS assay for quantifying coproporphyrins as organic anion-transporting polypeptide biomarkers
We talk to Ragu Ramanathan about his work on LC–MS/HRMS assay for quantifying coproporphyrins as organic anion-transporting peptide biomarkers
Bioanalysis Zone and Bioanalysis welcome unsolicited submissions to both the journal and website!
As the 2017 BOSCA winner, we spoke to Dr Henion about some of the most groundbreaking and pivotal moments in his career.
Bioanalysis Zone today announced the winner of the Bioanalysis Outstanding Contribution Award – BOSCA – awarded to bioanalytical scientists for outstanding work and contribution to the community.
2D-LC–MS/MS to measure cleaved high-molecular-weight kininogen in human plasma as a biomarker for C1-INH-HAE
This research article describes a reagent-free LC–MS assay that has been developed for the quantitation of cHMWK, which was shown to be elevated in plasma of C1-INH-HAE patients due to C1-INH deficiency relative to that of healthy subjects.
A Swedish research team has identified a method of drug and disease detection through the analysis of various compounds in exhaled breath.
Issue 23 of Bioanalysis volume 9 is now available, including an editorial discussing the matrix effects, a methodology on assay signaling and a White Paper on the rise of hybrid LBA/LCMS immunogenicity assays.
Development of Native and Denaturing LC-MS Methods for Characterization of Cysteine-Linked Antibody Drug Conjugates Using a Non-Toxic Mimic
Here we utilize a cysteine-linked antibody fluorophore conjugate to show how LC-MS methods may be optimized using a non-toxic ADC-mimic. The ADC-mimic was used to develop native and reduced SEC-MS conditions. The reduced mimic’s heavy and light chains, as well as its IdeS-proteolysis fragments, were used to develop reversed-phase LC-MS methods. A tryptic digest of the ADC mimic was used to develop a peptide mapping LC-MS method.